Kolon TissueGene KRX:950160KOSDAQ
코오롱티슈진 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days4
DART filings, 7 days0
Articles tracked24since Sep 11
In Q2 2026, Kolon TissueGene reported revenue of ₩1m, down 41.3% year on year, and an operating loss of ₩5m. Kolon TissueGene (코오롱티슈진) appeared in 4 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 28 with 1 article.
Filing signals 4 quarters of losses Litigation Screener
Kolon TissueGene quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩1m | -41.3% | −₩5m | ₩33m |
| Q1 2026 | ₩1m | +8.6% | −₩4m | −₩68m |
| Q4 2025 derived | ₩1m | +7.3% | −₩6m | −₩87m |
| Q3 2025 | ₩1m | -21.7% | −₩3m margin −208.4% | −₩4m |
| Q2 2025 | ₩1m | +32.4% | −₩4m | −₩40m |
| Q1 2025 | ₩1m | -2.9% | −₩4m | −₩4m |
| Q4 2024 derived | ₩1m | -6.4% | −₩5m | −₩14m |
| Q3 2024 | ₩2m | +15.2% | −₩4m margin −276.8% | −₩4m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Kolon TissueGene top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
Latest Kolon TissueGene news Korean headlines
-
코오롱티슈진, 전승호 대표이사 체제로 변경
2 more on this story · 2 outlets
- 코오롱티슈진, 전승호 대표이사 체제로 변경이데일리 · Sep 18 18:17
- 코오롱티슈진, 전승호 대표이사 체제로 변경이데일리증권 · Sep 18 18:17
-
코오롱티슈진, 노문종 대표 사임…전승호 대표 단독 체제로
3 more on this story · 3 outlets
- 코오롱티슈진, 전승호 단독대표 체제로…노문종 대표 사임뉴스1 · Sep 18 17:35
- 코오롱티슈진, 노문종 대표 사임⋯전승호 단독대표 체제 전환아이뉴스24 · Sep 18 18:26
- 코오롱티슈진, 전승호 단독대표 체제 전환…노문종 대표 사임더바이오 · Sep 18 18:29